Home ENGLISH Page 2

ENGLISH

Latest

Relay adds executives to its chemistry, R&D teams as it transitions to the development...

admin -
0

SmartZyme spins off protein tech company for a metabolic disease partnership with Hemoshear

admin -
0

With Gilead and rivals deep in phase 3, FDA unveils draft guidance on NASH...

admin -
0

Boehringer inks pact with Domain for GPCR neurology drugs

admin -
0

ASH18: Amgen’s anti-BCMA bispecific shines again, but CAR-T threat remains

admin -
0

Finding of dementia genes could speed drug discovery in Alzheimer’s and other brain disorders

admin -
0

Regeneron records 80% complete response rate in lymphoma trial

admin -
0

ASH18: New data can’t lift Bluebird Bio’s depressed shares

admin -
0

ASH18: J&J shells out $500M to sew up Argenyx’s blood cancer hopeful cusatuzumab

admin -
0

Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH

admin -
0

Principia chalks up a win for its BTK autoimmune program

admin -
0

Lundbeck and Otuska’s brexpiprazole hits the mark in PTSD trial

admin -
0

AstraZeneca’s TLR9 oligonucleotide misses goal in asthma phase 2

admin -
0

Making CRISPR-Cas9 gene editing safer with artificial intelligence

admin -
0

Chutes & Ladders—Abeona fires CEO Carsten Thiel

admin -
0

Bayer moves to refocus on its core pharma R&D, cutting 12,000 jobs

admin -
0

Inflazome brings on ex-Novartis executive as CMO after €40M VC round

admin -
0

Brexit ‘could be an opportunity for U.K. clinical research’

admin -
0
123...1,468Page 2 of 1,468
©